


Vaccine recipients

Placebo recipients



Prospectively
follow-up all
participants



Infections
(asymptomatic
screening)



60/1000 vaccine recipients
60/1000 placebo recipients

Symptomatic
screening



10/60 vaccine recipients
50/60 placebo recipients

Infections
requiring
hospital
admissions



0/60 vaccine recipients
0/60 placebo recipients

Infections
resulting in
death



0/60 vaccine recipients
0/60 placebo recipients

Participants and study staff
blinded to treatment
allocation
(Double Blinded).